Background: In an open follow-up study we tested a treatment schedule of reduced combined radio- and chemotherapy in Hodgkin’s disease in limited stages with elevated risk factors (mediastinal bulky disease, systemic B symptoms, extranodal lesions and unfavorable histological subtypes) and in advanced stages. The aim of the study was to reduce the delayed complications of full-dose combined modality treatment while preserving its effectiveness. Material and Methods: From May 1985 to December 1988, 43 previously untreated patients entered the study. Treatment consisted of CVPP/ABVB (cyclophosphamide, vinblastine, procarbazine, prednisolone/doxorubicin, bleomycin, vincristine, bendamustine) hybrid chemotherapy and involved-field, low-dose (25 Gy) radiation. Results: All patients could be evaluated for response to treatment and follow-up. Primary complete remission was reached in 35/43 (81%) patients, partial remission in 5/43 (12%), and 3/43 (7%) failed to respond. After a median observation period of 124 (108–143) months, 27/35 complete responders are still in first complete remission. The survival data are as follows: relapse-free survival at 5 years is 81.5%, at 10 years 70%; overall survival after 5 and 10 years 83% and 73%, respectively. So far, 8 patients relapsed and 8 patients died. The acute toxicity of the treatment program was moderate; concerning late toxicity we observed 2 secondary neoplasias (1 acute nonlymphocytic leukemia and 1 gastric carcinoma) in relapsed and heavily treated patients but none in the group of patients treated according to the protocol. Conclusions: Combined reduced dosage radio- and chemotherapy is effective in poor-risk Hodgkin’s disease and seems not to increase the risk of secondary malignancies.

This content is only available via PDF.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.